Profile data is unavailable for this security.
About the company
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
- Revenue in CNY (TTM)3.26bn
- Net income in CNY453.31m
- Incorporated1994
- Employees2.88k
- LocationMayinglong Pharmaceutical Group Co LtdNo. 100, Nanhu Zhoujiawan, WuchangWUHAN 430064ChinaCHN
- Phone+86 2 787291519
- Fax+86 2 787291724
- Websitehttps://www.mayinglong.cn/index.html
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liaoning Chengda Biotechnology Co Ltd | 1.76bn | 420.34m | 11.36bn | 1.73k | 26.92 | 1.17 | -- | 6.45 | 1.01 | 1.01 | 4.26 | 23.41 | 0.1743 | 0.7061 | 1.61 | 1,016,911.00 | 4.16 | 10.63 | 4.27 | 11.01 | 81.48 | 85.74 | 23.87 | 39.56 | 20.80 | -- | 0.002 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
| Bio-Thera Solutions Ltd | 711.46m | -370.90m | 11.48bn | 1.17k | -- | 10.49 | -- | 16.13 | -0.8957 | -0.8957 | 1.72 | 2.64 | 0.3099 | 0.9439 | 6.06 | 609,647.70 | -16.15 | -23.62 | -23.70 | -30.81 | 71.41 | 79.76 | -52.13 | -106.72 | 0.8258 | -367.55 | 0.3515 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.73bn | 511.96m | 11.62bn | 2.55k | 22.65 | 1.48 | -- | 4.26 | 0.5447 | 0.5447 | 2.90 | 8.35 | 0.2186 | 1.58 | 0.8134 | 1,071,832.00 | 4.06 | 3.48 | 5.61 | 4.78 | 46.09 | 38.93 | 18.56 | 10.08 | 2.35 | -- | 0.2862 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 1.80bn | 514.80m | 11.77bn | 2.47k | 22.87 | 2.70 | -- | 6.55 | 1.18 | 1.18 | 4.11 | 9.95 | 0.36 | 2.68 | 6.66 | 727,792.60 | 10.31 | -- | 11.11 | -- | 39.78 | -- | 28.63 | -- | 5.51 | -- | 0.0551 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
| Sansure Biotech Inc | 1.20bn | 384.73m | 11.86bn | 2.01k | 31.25 | 1.58 | -- | 9.86 | 0.6448 | 0.6448 | 2.06 | 12.77 | 0.1377 | 0.8274 | 1.41 | 599,646.90 | 4.14 | 26.74 | 4.69 | 30.97 | 74.82 | 67.47 | 30.06 | 42.01 | 7.94 | -- | 0.0589 | 22.40 | -84.39 | 27.12 | -81.22 | 121.89 | 64.08 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.26bn | 453.31m | 11.99bn | 2.88k | 26.44 | 3.06 | -- | 3.68 | 1.05 | 1.05 | 7.56 | 9.08 | 0.6482 | 5.87 | 11.13 | 1,130,851.00 | 9.26 | 10.82 | 11.03 | 13.47 | 42.87 | 41.18 | 14.29 | 14.08 | 5.18 | -- | 0.0729 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.18bn | 208.25m | 12.13bn | 1.55k | 58.24 | 5.39 | -- | 10.27 | 0.9769 | 0.9769 | 5.54 | 10.55 | 0.3743 | 1.21 | 4.71 | 764,598.40 | 6.69 | 5.86 | 9.15 | 7.59 | 63.15 | 55.41 | 17.87 | 17.20 | 1.08 | 33.77 | 0.3356 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.43bn | 523.43m | 12.88bn | 8.41k | 24.80 | 1.80 | -- | 2.00 | 0.202 | 0.202 | 2.49 | 2.78 | 0.5568 | 2.39 | 4.60 | 764,058.90 | 5.02 | 6.77 | 7.25 | 10.50 | 54.36 | 63.24 | 9.02 | 11.10 | 1.53 | 40.71 | 0.1459 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
Data as of May 31 2024. Currency figures normalised to Mayinglong Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
9.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 18.31m | 4.25% |
| Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 7.78m | 1.81% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 2.97m | 0.69% |
| First-Trust Fund Management Co., Ltd.as of 31 Dec 2023 | 2.32m | 0.54% |
| HFT Investment Management Co., Ltd.as of 31 Dec 2023 | 2.12m | 0.49% |
| HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 1.99m | 0.46% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 1.94m | 0.45% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 1.84m | 0.43% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.70m | 0.40% |
| First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 1.41m | 0.33% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
